Is The Global Generic Drug Market Slowing Down?

Driven by a strong environmental headwind, both within and outside the country, several pharma companies in India have recently started raising a red flag on their future earning guidance for the stock market, though citing quite different reasons altogether. Quoting … Continue reading

Making New Cancer Drugs Cost-effective

The prices of new cancer drugs are increasingly becoming unsustainable across the world, and more so in India. A sizable number of poor and even middle-income patients, who spend their entire life’s savings for the treatment of this dreaded disease, … Continue reading

Patented Drugs: A Dangerous Pricing Trend Impacting Patient Access

The upcoming trend of jaw dropping high prices for new patented drugs sends a ‘storm signal’ to many stakeholders, especially for its adverse impact on patient access. Even more intriguing, such high and insane prices are being fixed rather arbitrarily, … Continue reading

Democratization of Healthcare: An Evolving Trend Driven By Cutting-Edge Technology

We have stepped on to a fascinating era of yet another disruptive innovation in a newly carved out space of the healthcare domain. Such initiatives are driven by path breaking ideas, which are being translated into reality with the application … Continue reading

Evolving Trend Of Patient Engagement In Treatment Decisions

Slowly but steadily the process of taking treatment decisions for the patients is undergoing a metamorphosis, where well informed patients no longer want to play just a passive role. These patients want the doctors to take a final decision on … Continue reading

Global New Product Launches: Recent Success Trend Unflattering?

New products are the lifeblood for any company, including the pharmaceutical players. Business performance and sustainable growth of the pharmaceutical industry, as a whole depend on quality of R&D output in terms of ‘New Molecules’, followed by successful development and … Continue reading

‘Patent Pool’ – is GSK setting a new trend for the global pharmaceutical industry?

On February 13, 2009, The Guardian reported that Andrew Witty, CEO of GlaxoSmithKline (GSK) announced some significant changes to the way his company will operate in the developing countries of the world. GSK, as Witty said, will: • “Cut its … Continue reading